Revenue for the quarter came in at
Following the recent decision to initiate a global voluntary recall (pharmacy / retail level) of ranitidine products including Zinetac in
Exceptional items recognised in the quarter includes financial impact related to the voluntary recall of Zinetac, as detailed below:
As part of this review, GSK India has assessed the current financial impact of the voluntary recall and has taken a financial impairment of INR
The reported sales number for the quarter declined due to portfolio optimization and voluntary recall of Zinetac. Adjusting for the same the underlying sales growth is +6%.
Our YTD underlying sales growth stands at +13% and EBIDTA margins have improved on account of various operation efficiencies, cost saving and working capital initiatives taken during the year.
As part of our unwavering support to serving patients, GSK India will continue to invest to bring innovative medicines and vaccines to
Commenting on the results, A. Vaidheesh, Managing Director,
The results were impacted due to voluntary global recall of ranitidine products including Zinetac in
Our YTD underlying sales growth stands at +13% with our key promoted brands recording +20% growth.
We continue to witness strong performance of Nucala (Mepolizumab) which is a humanised monoclonal antibody and indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
We successfully launched Menveo vaccine for protection against meningococcal disease.
At GSK we operate a global manufacturing network and keep our operations under regular review to ensure we deliver high-quality products that our patients need and deliver on our Innovation,
Media contact:
Tel: +91 22 2495 9595
Email: corporate-communication@gsk.com
(C) 2020 Electronic News Publishing, source